Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.